The chair of the FDA's Antimicrobial Drugs Advisory Committee criticized the agency's lack of a transparent, scientific process in approval of therapies to treat COVID-19, stating that "the trust the FDA has built and maintained over the past century is eroding." (New England Journal of Medicine)